Ratings C.Q. Pharmaceutical Holding Co., Ltd.

Equities

000950

CNE0000010K0

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
5.95 ^CNY	+1.19%		+4.57%	+19.72%

May. 06	China Grants Drug Registration Certificate to C.Q. Pharmaceutical's Anti-Inflammatory Drug	MT
Apr. 26	C.Q. Pharmaceutical Holding Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

The company's profit outlook over the next few years is a strong asset.
The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
The company's share price in relation to its net book value makes it look relatively cheap.
Analysts covering this company mostly recommend stock overweighting or purchase.
The opinion of analysts covering the stock has improved over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
C.Q. PHARMACEUTICAL HOLDING CO., LTD.	+19.72%	1.42B	-
MCKESSON CORPORATION	+21.93%	73.38B	C+
CARDINAL HEALTH, INC.	-1.71%	24.13B	C+
SINOPHARM GROUP CO. LTD.	+7.33%	8.78B	C
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+10.34%	8.59B	B
HUADONG MEDICINE CO., LTD	-19.80%	8.06B	B-
H. LUNDBECK A/S	+14.16%	5.26B	B-
EBOS GROUP LIMITED	-0.03%	4.21B	B-
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	+12.70%	4.17B	B+
GALENICA AG	-2.54%	3.89B	B

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes